Brief: Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease

Equillium

27/03/2025 11:13

March 27 (Reuters) - Equillium Inc EQ.O:

EQUILLIUM ANNOUNCES RESULTS OF THE PHASE 3 EQUATOR STUDY OF ITOLIZUMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

EQUILLIUM INC - ITOLIZUMAB DID NOT IMPROVE RESPONSE RATES AT DAY 29

EQUILLIUM INC - ITOLIZUMAB ACHIEVED STATISTICAL SIGNIFICANCE IN LONGER-TERM OUTCOMES

EQUILLIUM INC - BREAKTHROUGH THERAPY DESIGNATION REQUEST SUBMITTED TO FDA, FEEDBACK EXPECTED DURING MAY 2025

Source text: ID:nBw7QkrD2a

Further company coverage: EQ.O

 ((Reuters.Briefs@thomsonreuters.com;))